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Prosthetic vascular graft infection is devastating and frequently fatal. Cure requires removal of the graft and
reperfusion by placement of a new graft. However, no evidence based guidelines exist for management
where removal of the graft is not possible. We describe a patient who lived in a state of chronic infection sup-
pression through outpatient parenteral antimicrobial therapy (OPAT) over a period of 32months, and outline
the challenges experienced and strategies used to suppress infection in the face of escalating antimicrobial
resistance. To date there have been very few reports of OPAT used in the palliative context and this case illus-
trates the microbiological issues that can arise and the importance of the full OPAT multi-disciplinary team in
managing these issues and optimising the patient's quality and length of life.
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Prosthetic vascular graft infection is a devastating complication,
with a mortality rate of up to 75%.1 Cure requires removal of the graft
and reperfusion by placement of a new graft.2 However, no evidence
based guidelines exist for management where removal of the graft is
not possible. We describe a patient who lived in a state of chronic
infection suppression through outpatient parenteral antimicrobial
therapy (OPAT) over a period of 32months, and outline the chal-
lenges experienced and strategies used to suppress infection in the
face of escalating antimicrobial resistance. To date there have been
very few reports of OPAT used in the palliative context and this case
illustrates the microbiological issues that can arise and the impor-
tance of the full OPAT multi-disciplinary team in managing these
issues and optimising the patient's quality and length of life.Case report
A 69-year-old woman presented acutely with an aorto-enteric ﬁs-
tula. She underwent endovascular aneurysm repair and cross-over
graft. Post-operatively she developed methicillin-resistant Staphylo-
coccus aureus (MRSA) graft infection. Further operative intervention
was considered impossible due to her complex vascular history and
frailty.Following several months of inpatient intravenous antibiotics she
was referred for OPAT as it was hoped that OPAT would offer a pallia-
tive option whilst maintaining the patient's quality of life. Her anti-
microbial history, current medications, microbiology and drug
allergy status were reviewed and there were no oral antimicrobial
options for her MRSA infection. She commenced OPAT administered
by her partner at home with weekly medical and nursing reviews,
line dressing changes and blood tests. The wound over her cross-over
graft broke down exposing the graft: dressings were managed by the
community nurse team and the patient herself.
Fig. 1 illustrates the patient's C-reactive protein (CRP), microbiology
and antimicrobial regimes during her 32months of OPAT. There were
four occasions on which she reported rigors and malaise to the OPAT
team: on all of these she was apyrexial and clinically well when subse-
quently reviewed but had an increased CRP and positive blood cultures.
CRP measurements between these episodes remained between 40 and
60mg/L in keeping with chronic low level sepsis. She also had chronic
anaemia, hypoalbuminaemia and failure to gain weight.
There were 4 phases in her OPAT management:
1. Daptomycin (6mg/kg daily) with oral co-amoxiclav (625mg
three times daily).
The patient was initially commenced on daptomycin as an inpa-
tient. Prior to discharge from hospital she developed cellulitis asso-
ciated with her exposed cross-over graft. Oral co-amoxiclav was
added as it was felt that her cellulitis was most likely to be caused
by Gram negative organisms given the proximity of the graft to
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Fig. 1. CRP, blood culture isolates and antimicrobial regimes during OPAT.
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remained clinically stable with improvement in her CRP.
2. Daptomycin with ertapenem (1 g daily).
After around eight months she reported rigors, sweats and mal-
aise. Blood culture grew co-amoxiclav-resistant Proteus mirabilis
and Morganella sp. She was admitted brieﬂy and after discussion
by the OPAT team was switched from oral co-amoxiclav to intra-
venous ertapenem, together with ongoing daptomycin. Again
her CRP improved and she was discharged back to OPAT.
3. Daptomycin with ciproﬂoxacin (750mg bd orally) or ertapenem
(46 weekly rotation).
After a further eight months the patient again reported two rigors.
Blood cultures grew ertapenem-resistant Enterobacter cloacae and
ertapenem was switched to oral ciproﬂoxacin. However the CRP
was slow to settle and further blood cultures grew ciproﬂoxacin-
resistant Escherichia coli. The decision was taken by the OPAT team
to rotate ertapenem and oral ciproﬂoxacin at 46week intervals.
Her CRP again improved and she remained well. The introduction of
periods of oral therapy allowed her and her partner to go on holiday
within the UK through simplifying her daily intravenous regime.
4. Linezolid (600mg twice daily) with alternating ertapenem and
ciproﬂoxacin.
Sixteen months later she once again presented with symptoms of
infection and blood cultures grew daptomycin-resistant Entero-
coccus faecium. Daptomycin was switched to oral linezolid: this
agent had not been used previously because of concomitant long
term anti-depressant therapy. The OPAT team had previously
recognised the potential need to use linezolid and had arranged
psychiatric assessment. It was deemed acceptable to withdraw
her antidepressant therapy at this point, allowing use of line-
zolid. She received this for two weeks before being switchedback to daptomycin. She also continued her Gram-negative anti-
microbial regime.
Unfortunately the patient was admitted under the vascular team
six weeks later with acute onset ischaemic limb pain. She underwent
an emergency graft explantation, then bilateral above knee amputa-
tions but continued to experience limb ischaemia. No further surgery
was possible and she was discharged home with palliative care and
died one week later.
Discussion
The incidence of prosthetic graft infections is 16%3 with MRSA
the most common causative organism.4 There are no guidelines for
patients who cannot undergo surgery. One study reported that
patients treated only with long term suppressive antimicrobial ther-
apy survived a median of 41months.5 As seen in this case long term
antibiotics can result in increasing antibiotic resistance and complex
management issues.
This patient's management demonstrated the importance of a
robust OPAT service structure with regular monitoring, clear lines of
communication with the patient and protocols for escalation. Fur-
thermore the OPAT multi-disciplinary team was essential in review-
ing the microbiological data and providing expert consensus to
optimise the management of these difﬁcult infections.6,7 The patient's
partner was an integral member of the team and took pride in admin-
istering her treatment without complications.8
OPAT was invaluable to this patient and her family. Without OPAT
she would have remained in hospital for the last three and a half years
of her life. Although her management could be regarded as an OPAT
‘success’, previous UK and USA OPAT guidelines would have classed her
outcome as a failure of OPAT.6,9 The recent OPAT UK updated Good
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palliative measure in patients with incurable prosthetic material infec-
tions and propose outcomes based on treatment aim (in this case pallia-
tion) and whether the intended treatment aim was achieved.10
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